Medicare AdvantageDocumentationMedium impact
MA11.004n, Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)
Independence Blue Cross·Urology·Medical Policy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Policy MA11.004n establishes medical necessity criteria, coding guidelines, and coverage updates for minimally invasive treatments addressing urinary outlet obstruction due to benign prostatic hyperplasia (BPH). This recent policy (effective 03/24/2025) updates medical necessity requirements, billing code guidance, and general informational parameters for BPH treatment procedures. Billing teams must review updated criteria to ensure claims meet current medical necessity standards and use correct coding.
Action Required
By 03/24/2025: Billing team and providers must review and implement MA11.004n policy changes for all BPH minimally invasive treatment claims. (1) Obtain full policy text from https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma11-004n-minimally-invasive-treatments-f to identify specific affected billing codes and updated medical necessity criteria. (2) Update clinical documentation templates to capture all required medical necessity elements per new policy. (3) Train providers on updated coverage guidelines for BPH procedures. (4) Configure billing system to apply new medical necessity validation rules at claim entry. (5) Flag all existing BPH procedure claims for review against updated criteria. Failure to comply may result in claim denials for insufficient medical necessity documentation or incorrect coding.